GSK, Valeant Dodge Sham Patent Suit Claims In Wellbutrin Row

Law360, New York (May 11, 2012, 4:56 PM EDT) -- A Pennsylvania federal judge on Friday granted a move by GlaxoSmithKline PLC and Valeant Pharmaceuticals International to toss claims brought by purchasers of depression medication Wellbutrin XL in an antitrust class action, finding no sham patent suits were brought to delay the drug's generic version.

U.S. District Judge Mary A. McLaughlin ruled that the direct and indirect purchasers of Wellbutrin XL and its generic equivalent failed to prove that four patent infringement lawsuits and a citizen petition brought by Biovail Corp., which merged with Valeant in...
To view the full article, register now.